Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Multiple Myeloma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Burkitt Lymphoma 12Lymphoma, Mantle-Cell 6Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myeloid, Acute 5Neoplasm Metastasis 4Leukemia 4Immunoglobulin Light-chain Amyloidosis 4Breast Neoplasms 4Blast Crisis 4Vomiting 3Smoldering Multiple Myeloma 3Myelodysplastic Syndromes 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Hodgkin Disease 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmacytoma 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Nausea 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2

Interventions

fludarabine phosphate 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Cyclophosphamide 7Mycophenolic Acid 6Lenalidomide 6Dexamethasone 6Tacrolimus 5Bortezomib 4Sirolimus 3ixazomib 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2Calcium Dobesilate 2Antilymphocyte Serum 2Allopurinol 2talquetamab 1sargramostim 1pomalidomide 1montanide ISA 51 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia, Plasma Cell × dexamethasone 21-phosphate × Clear all
NCT02547662 2023-10-30

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Mayo Clinic

Phase 2 Completed
17 enrolled 13 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡